On this episode of Stock Movers:
- NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade.
- GSK shares dropped as approval of the British pharma company’s blood cancer drug for a later-than-expected treatment line raised concerns about the medicine’s sales potential.
- Accor shares rose after 3Q earnings in which the hotelier raised its guidance on the back of improved cost discipline. It also announced a new €100 million buyback in 4Q.
See omnystudio.com/listener for privacy information.
